IMSB 301
Alternative Names: IMSB-301Latest Information Update: 22 Aug 2024
At a glance
- Originator ImmuneSensor
- Class Anti-inflammatories; Small molecules
- Mechanism of Action CGAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 19 Aug 2024 ImmuneSensor Therapeutics receives HREC and TGA approval for phase I trial for Autoimmune disease (In volunteers) in Australia .
- 01 May 2024 ImmuneSensor plans a phase I trial for Autoimmune disorders (In Volunteers) in 2024
- 01 May 2024 Preclinical trials in Autoimmune disorders in USA (PO)